Search | Clinical Trials Finder

Conditions: Multiple Sclerosis
Interventions: ofatumumab with PRF, ofatumumab with AI; Combination Product
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Fullerton, California • Aurora, Colorado • Basalt, Colorado + 9 more

Conditions: Relapsing Multiple Sclerosis (RMS)
Interventions: Ublituximab, Teriflunomide, Oral Placebo, IV Placebo; Biological · Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 14
States / cities: Carlsbad, California • Long Beach, California • Pasadena, California + 11 more

Conditions: Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Interventions: Ocrelizumab, Lumbar Puncture, Methyloprednisolone, Antihistamine; Drug · Procedure
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 12
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Multiple Sclerosis (MS)
Interventions: Fingolimod, Ofatumumab, Siponimod, Fingolimod placebo, Siponimod placebo, Ofatumumab placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 6
States / cities: Little Rock, Arkansas • Los Angeles, California • Washington D.C., District of Columbia + 3 more

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: dimethyl fumarate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 62
States / cities: Birmingham, Alabama • Tuscon, Arizona • Los Angeles, California + 57 more

Conditions: Multiple Sclerosis, Relapsing Multiple Sclerosis, Advancing Multiple Sclerosis
Interventions: Siponimod; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 54
States / cities: Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 49 more

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Blood draw for future biomarker analysis; Other
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Multiple Sclerosis
Interventions: Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more

Conditions: Multiple Sclerosis
Interventions: Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Relapsing Multiple Sclerosis (RMS)
Interventions: Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • Hollywood, Florida • Wellesley, Massachusetts + 4 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Ofatumumab; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 562 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 25
States / cities: Fullerton, California • Aurora, Colorado • Newark, Delaware + 21 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Remibrutinib, Teriflunomide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 52
States / cities: Phoenix, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more

Conditions: Multiple Sclerosis
Interventions: RPC1063; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 2,494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 19
States / cities: Phoenix, Arizona • Berkeley, California • Fresno, California + 15 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Tolebrutinib, Teriflunomide HMR1726, Placebo to match Tolebrutinib, Placebo to match Teriflunomide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 43
States / cities: Cullman, Alabama • Phoenix, Arizona • Arcadia, California + 38 more

Conditions: Multiple Sclerosis
Interventions: Rebidose®; Device
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Multiple Sclerosis, Myasthenia Gravis
Interventions: CC-97540, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Birmingham, Alabama • Irvine, California • Aurora, Colorado + 12 more

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD, EHP-101 50 mg BID; Drug
Lead sponsor: Emerald Health Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Cullman, Alabama • Fullerton, California • Port Orange, Florida

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: GA Depot, Placebo; Drug · Other
Lead sponsor: Mapi Pharma Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,016 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 11
States / cities: Birmingham, Alabama • Cullman, Alabama • Pasadena, California + 8 more

Conditions: Relapsing Multiple Sclerosis
Interventions: CYB704, Ocrevus-EU, Ocrevus-US; Biological
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Maitland, Florida • Ormond Beach, Florida

Conditions: Multiple Sclerosis
Interventions: AZD0120 - Regimen 1, AZD0120 - Regimen 2; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Ofatumumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Pomona, California + 15 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Atacicept, Placebo matched to atacicept; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Phoenix, Arizona • Atlanta, Georgia • Northbrook, Illinois + 5 more

Conditions: Multiple Sclerosis
Interventions: Teriflunomide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 75
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 67 more

Search by objective public record fields.

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis

Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS

Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients

Study of Evobrutinib in Participants With RMS

Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS)

A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

The Multicenter, Open-label, Single-use Autoinjector Convenience Study

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)

Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients